Arena Pharmaceuticals (NASDAQ:ARNA) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
Several other equities research analysts also recently issued reports on ARNA. Zacks Investment Research raised Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Citigroup increased their price objective on Arena Pharmaceuticals from $37.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Leerink Swann reissued a “positive” rating and issued a $56.00 price objective (up from $53.00) on shares of Arena Pharmaceuticals in a research note on Wednesday, January 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $45.00 price objective on shares of Arena Pharmaceuticals in a research note on Wednesday, January 17th. Finally, Credit Suisse Group assumed coverage on Arena Pharmaceuticals in a research note on Wednesday, January 17th. They issued an “outperform” rating and a $44.00 price objective for the company. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $45.13.
Shares of Arena Pharmaceuticals (NASDAQ ARNA) opened at $40.20 on Tuesday. The stock has a market capitalization of $1,580.00, a PE ratio of -42.77 and a beta of 1.51. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.42 and a quick ratio of 4.32. Arena Pharmaceuticals has a one year low of $11.30 and a one year high of $44.50.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.